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ABSTRACT
Aims To assess the additive effect of dorzolamide
hydrochloride 2% on the diurnal intraocular pressure
(IOP) curve and retrobulbar haemodynamics in patients
with primary open-angle glaucoma (POAG) treated with
morning-dosed bimatoprost 0.03%.
Methods Twenty-ﬁve patients with POAG were
evaluated in a prospective, single-masked study. After
a 1 week run-in period with bimatoprost all patients
were treated with bimatoprost dosed once in the
morning for 1 month, after which dorzolamide was
added twice daily for 2 months. Goldmann applanation
IOP, arterial blood pressure (ABP) and heart rate were
measured every 2 h for 24 h and diurnal ocular perfusion
pressure (OPP) was calculated. Colour Doppler imaging
(CDI) of the ophthalmic artery (OA) and the central
retinal artery (CRA) was recorded ﬁve times daily. All
measurements were taken after the two phases of
treatment and were compared.
Results The mean baseline IOP was 14.863.5 mmHg.
Mean IOP following bimatoprost monotherapy
(12.862.9 mmHg) and after 2 months of dorzolamide
adjunctive therapy (12.262.6 mmHg) were not
statistically signiﬁcantly different (p¼0.544). Only at the
4:00 h time point was IOP signiﬁcantly reduced using the
bimatoprost/dorzolamide combined treatment
(p¼0.013). The 24 h IOP ﬂuctuations were lower when
dorzolamide was added (6.062.3 mm Hg vs
4.661.5 mm Hg, p¼0.0016). Repeated analysis of
variance detected a signiﬁcant decrease of vascular
resistance in the OA (p¼0.0167) with adjunctive
dorzolamide treatment.
Conclusions The addition of dorzolamide to morning-
dosed bimatoprost had an additive hypotensive effect
only on the night-time IOP curve at 4:00 h and resulted in
a lower IOP ﬂuctuation. Dorzolamide added to
bimatoprost may reduce vascular resistance in the OA.
INTRODUCTION
The pathogenesis of glaucoma can involve both
mechanicalandvascularfactors,eitherindependently
or by inﬂuencing one another. Ocular ischaemia,
induced primarily by vasospasm and autoregulatory
dysfunction, intensiﬁed by elevated intraocular pres-
sure (IOP) may trigger glutamate-mediated toxicity
and neurotrophic factor withdrawal and contribute
to apoptotic retinal ganglion cell death.
1 Numerous
studies have shown evidence of systemic circulatory
disturbances,perfusiondeﬁcitsincerebralvesselsand
reduced ﬂow in retrobulbar and ocular vessels in
patients with glaucoma.
23
Lowering of IOP remains the only current ther-
apeutic approach for preserving visual function in
patients suffering from glaucoma and is the goal of
currently available glaucoma treatment. It is well
established that some patients with glaucoma
beneﬁt from achieving low target IOP.
4 Multiple
medical treatments are often required to achieve
such IOP levels. The efﬁcacy of antiglaucoma
therapy should be assessed not only on the basis of
one measurement of IOP during ofﬁce hours but
also on the basis of diurnal IOP curves. Large
diurnal ﬂuctuations in IOP have been shown to be
associated with deterioration of the visual ﬁeld in
patients with glaucoma
5 and IOP ﬂuctuations have
been identiﬁed outside ofﬁce hours.
6
Some patients with glaucoma continue to prog-
ress despite well-controlled IOP. A number of
studies report a relationship between ocular blood
ﬂow deﬁcits and glaucoma progression
7 or severity.
8
Improvement of ocular and retrobulbar perfusion
may be effective in preventing visual ﬁeld progres-
sion in patients with glaucoma.
Nocturnally induced lowering of arterial blood
pressure (ABP), caused by a reduction in sympathetic
activity during the night, leads to a decrease in heart
rate (HR) and cardiac output and, when coupled
with a concurrent increase in IOP, may impair the
ocular perfusion pressure (OPP) and blood ﬂow. It
has been reported that patients with glaucoma with
greater nocturnal ABP reduction demonstrated
greater progression of optic nerve damage.
2
Prostaglandin analogues (PGAs) and prostamides
are potent IOP-lowering agents widely used in
glaucoma treatment. PGAs and prostamides reduce
IOP to a similar extent during the night and day.
9
Some studies
10 suggest that evening-dose PGAs
provided better IOP control in the daytime than in
the night-time hours. The haemodynamic charac-
teristic of PGAs is uncertain.
Topical carbonic anhydrase inhibitors (TCAIs)
are highly effective at night.
9 Dorzolamide, the ﬁrst
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Clinical scienceTCAI available on the market, has been repeatedly shown to
have a positive impact on ocular haemodynamics.
11
Combination of prostamides and TCAIs, two drugs with
different mechanisms of hypotensive action, may result in an
additive effect on the reduction of IOP
12 13 and a change in
ocular blood ﬂow.
The purpose of the study was to examine the additive effect
of dorzolamide hydrochloride and bimatoprost on both the
diurnal IOP curve and retrobulbar haemodynamics in patients
with primary open-angle glaucoma (POAG).
MATERIALS AND METHODS
The study was performed according to the tenets of the
Declaration of Helsinki and was approved by an institutional
review board at the Military Health Service Institute, in Warsaw.
Signed informed consent was obtained from all patients before
study enrolment.
Twenty-six patients (aged 60.3610.4 years, range 35e80; 20
women) with a diagnosis of early to moderate POAG receiving
PGA or prostamide monotherapy were initially enrolled in an
open label, prospective, interventional, single-masked study.
After a 1 week run-in period with bimatoprost 0.03%, all
patients were treated with bimatoprost 0.03% dosed once daily
in the morning (9:00 h) for 1 month, after which dorzolamide
hydrochloride 2% was added twice daily (8:00 and 20:00 h) for
2 months. One patient was excluded from the study because of
dorzolamide intolerance.
POAG was diagnosed on the basis of a glaucomatous
appearance of the optic disc (cup/disc ratio >0.6 or an inter-
ocular cup/disc ratio asymmetry $0.2, and at least one of the
following abnormalities: thinning of the rim, notching, nerve
ﬁbre layer defects or peripapillary atrophy), correlating with
visual ﬁeld defects in two consecutive central 24-2 program of
Humphrey threshold perimetry tests, according to the European
Glaucoma Society (EGS) diagnostic criteria (abnormal glaucoma
hemi-ﬁeld test or cluster of three non-edge contiguous points at
the <5% level on the pattern deviation plot with at least one
point at the <1% level or corrected pattern deviation (CPSD)
<5%, with <25% ﬁxation losses and false-positive and false-
negative responses). Early and moderately glaucomatous loss
was deﬁned according to the classiﬁcation of Hodapp et al
14,
based on the mean defect (MD) index of visual ﬁelds less than e
6 dB (decibels) and e 12 dB but more than  6 dB, respectively,
and on the basis of a vertical cup/disc ratio <0.8. Patients of
either sex, aged $18 years with bilateral POAG, without
signiﬁcant cardiac or pulmonary conditions were eligible for the
study.
Patients with ocular hypertension, secondary glaucoma,
history of intraocular surgery, trauma, inﬂammation, diabetic
retinopathy or other progressive retinal disease, myopia above
e6.0 dioptres, central corneal thickness (CCT) <500 nm and
>600 nm were excluded from the study, as were pregnant or
nursing women.
After a 1 week run-in period with bimatoprost 0.03% (base-
line visit) best corrected visual acuity (BCVA), Goldmann
applanation tonometry (GAT), slit-lamp and stereo optic disc
evaluation, HR (radial pulse) and systolic and diastolic brachial
blood pressure (BP) measurement (sphygmomanometry) were
performed. After 1 month of bimatoprost treatment (control
visit) and after 2 months of combined bimatoprost/dorzolamide
treatment (ﬁnal visit) all patients were admitted to hospital for
24 h. Goldmann IOP, BP and HR measurements were taken
every 2 h and colour Doppler imaging (CDI) measurements were
taken ﬁve times over 24 h. Ocular haemodynamics were assessed
by CDI, using the LOGIQ 7 CDI System (General Electric
Medical Systems, Milwaukee, Wisconsin, USA) with a 6.7 MHz
linear probe, at 18:00, 22:00, 2:00, 4:00 and 6:00 h, by the same
investigator, who was masked to the individual treatment that
the patients were receiving. Peak systolic velocity (PSV) and end-
diastolic velocity (EDV) were measured in the ophthalmic artery
(OA) and the central retinal artery (CRA), and Pourcelot’s
resistance index (RI) was calculated for each vessel. Flow
velocity in the OA was measured close to its crossing the optic
nerve, and the angle between the transducer and the orientation
of the vessel was corrected. The CRA was localised along its
course through the optic nerve and measurement was performed
immediately behind the globe.
Mean systolic (SBP) and diastolic (DBP) blood pressures were
calculated as an average of all diurnal SBP and DBP readings.
Mean arterial pressure (MAP) was calculated as follows: DBP
+1/3 (SBPeDBP). Systolic ocular perfusion pressure (SOPP) and
diastolic ocular perfusion pressure (DOPP) were deﬁned as the
difference between the SBP and IOP, and between the DBP and
IOP, respectively. Mean ocular perfusion pressure (MOPP) was
calculated as follows: 2/3 MAPeIOP.
One study eye was chosen randomly for analysis. Twelve right
eyes and 13 left eyes were ﬁnally analysed. In an a priori power
analysis the sample size was calculated. With an n value of 25
we have at least 80% power to detect differences of at least 20%
at an a level of 0.05.
Statistical analysis of the data was carried out using SPSS 10.0
software. The comparisons of the values between the two
phases of treatment were carried out using paired t test and
repeated measure analysis of variance (ANOVA) with Bonferroni
adjustment for multiple comparisons. p Values <0.05 were
considered statistically signiﬁcant.
RESULTS
Twenty-ﬁve patients (aged 61.5610.9 years, range 35e80; 20
women) completed the entire study. The patient characteristics
are presented in table 1 (post run-in).
The mean baseline IOP at 10:00 h was 14.863.5 mmHg and
did not change at the same time point after 1 month of bima-
toprost monotherapy (14.263.1 mmHg). The mean IOP after
1 month of treatment with bimatoprost was 12.862.9 mmHg.
Dorzolamide did not lead to a signiﬁcant change in IOP after
2 months of combined treatment (12.262.6 mmHg, p¼0.188).
When pressures were compared at individual time points, there
was only one point at 4:00 h at which IOP control was signiﬁ-
cantly improved using the bimatoprost/dorzolamide combined
treatment (p¼0.013). The greatest IOP reduction under combined
Table 1 Characteristics of the patients
Variable Mean (SD) Range
Age (years) 61.5 10.9 35.0e80.0
IOP (mmHg) 14.8 3.5 11.0e24.0
Visual acuity (BCVA) 0.85 0.20 0.5e1.0
Visual ﬁeld (MD)  2.93 2.13  9.74e1.09
Visual ﬁeld (PSD) 14.72 7.43 4.27e34.14
GDxeVCC (NFI) 33.1 18.3 11.0e77.0
Central corneal thickness 560.8 30.3 503.0e600.0
Systolic blood pressure (mean) 116.4 8.4 90.0e160.0
Diastolic blood pressure (mean) 68.2 9.8 40.0e85.0
Heart rate (per min) 71.3 11.8 56.0e100.0
BCVA, best corrected visual acuity; MD, mean deviation; PSD, pattern standard deviation;
NFI, nerve ﬁbre index.
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Clinical sciencetreatment was observed at 10:00 and 16:00 h, and during the
night-time at 4:00 and at 6:00 h. The 24 h IOP ﬂuctuations,
deﬁned as the difference between the maximum and minimum of
IOP, were 6.062.3 mmHg on bimatoprost monotherapy and
4.661.5 mmHg on bimatoprost/dorzolamide combined treat-
ment (p¼0.0016). The mean IOPs at each time point after
bimatoprost and bimatoprost/dorzolamide combination treat-
ment are provided in ﬁgure 1.
The SBP, DBP, MPP and HR between the two phases of
treatment were evaluated and no statistically signiﬁcant differ-
ences were demonstrated (table 2).
The differences observed in PSV, EDV and RI in the OA and
CRA before and after adding dorzolamide are provided in tables
3 and 4. Dorzolamide caused a statistically signiﬁcant decrease in
the mean RI of the OA (p¼0.017). All other parameters assessed
by CDI measurements in the CRA and OA appeared to be stable,
although a tendency to an increase in PSVin the CRA at all time
points and EDV in the OA at night-time (from 22:00 to 4:00 h)
was observed.
DISCUSSION
To our knowledge this study represents the ﬁrst prospective
clinical trial to evaluate the impact of dorzolamide in addition to
bimatoprost treatment in patients with POAG on both the 24 h
IOP curve and retrobulbar haemodynamics.
Numerous studies have shown an augmented IOP-lowering
effect when dorzolamide was added to PGAs or b-blockers.
12 13
We hypothesised that the combination of two hypotensive
drugs, bimatoprost and dorzolamide, each with a different
mechanism of action, would induce an additive effect on the
reduction of IOP. The published literature lacks information on
the hypotensive effect of such a combination.
Our study did not show any additional statistically signiﬁcant
lowering effect when dorzolamide was added to morning-dosed
bimatoprost at all time points, except at 4:00 h. It is possible
that the relatively low IOP achieved on bimatoprost mono-
therapy may have contributed to the lack of a signiﬁcant
decrease in IOP after adding the dorzolamide. The results
obtained by Maruyama
13 with dorzolamide added to latano-
prost conﬁrm our observation. The addition of dorzolamide to
latanoprost reduced the IOP from 16.062.1 mmHg at the end of
latanoprost monotherapy to 15.061.3 mmHg, resulting in only
an additional mean IOP reduction of 5.6%. They also found a
higher (19.161.9 mmHg) baseline IOP compared with our study.
These observations are also in agreement with other studies
which found a smaller IOP-lowering effect of antiglaucoma
medications in patients with normal tension glaucoma (NTG).
15
In patients with NTG, bimatoprost produces a 19.9% reduction
in baseline IOP,
16 whereas in patients with pseudoexfoliative
glaucoma its efﬁcacy doubles (35%).
17 Arici et al
12 showed that
dorzolamide could be successfully combined with latanoprost to
reduce IOP in patients with high-pressure glaucoma (at a mean
baseline IOP of 26.8 mmHg), resulting in an additional 15%
reduction in the IOP (15.9e13.1 mmHg).
The results of our study demonstrated that bimatoprost/
dorzolamide combined treatment provided a signiﬁcantly more
stable diurnal and nocturnal IOP curve than bimatoprost mono-
therapy. The 24 h IOP ﬂuctuations were 4.6 and 6.0 mmHg,
respectively. The lowest value of IOP was observed on bimato-
prost monotherapy, starting 12 h after drug administration. This
result is in an agreement with other studies on the 24 h effect of
bimatoprost on IOP.
18 In our study, when dorzolamide was added
to bimatoprost the lowest 24 h value of IOP was still reported at
midnight (p¼0.518) as it was on bimatoprost monotherapy, and
additional statistically signiﬁcant IOP reduction was observed at
4:00 h (p¼0.013). In another study
19 dorzolamide has also
demonstrated lower night-time pressures than daytime pressures.
Nakamoto and Yasuda,
15 however, a showed greater additive
effect of brinzolamide when it was added to latanoprost in the
daytime (5.7%) than in the night-time (3.4%).
Figure 1 Mean intraocular pressure (IOP) readings (with the standard
deviation) during 24 h monitoring; bimatoprost monotherapy (IOP 1)
compared with bimatoprost/dorzolamide therapy (IOP 2).
Table 2 The mean intraocular pressure, blood pressure, ocular
perfusion pressure and heart rate on bimatoprost and
bimatoprost+dorzolamide treatment
Bimatoprost
Bimatoprost+
dorzolamide p Value
Intraocular pressure 12.862.9 12.262.6 0.1879
Systolic blood pressure 110.5617.9 108.8613.8 0.1673
Diastolic blood pressure 66.468.9 63.768.5 0.0564
Mean arterial pressure 81.1610.7 78.769.4 0.1050
Systolic ocular perfusion pressure 97.9618.0 96.5613.5 0.1582
Diastolic ocular perfusion pressure 53.769.2 51.468.1 0.0672
Mean ocular perfusion pressure 68.4611.0 66.469.1 0.2075
Heart rate 69.369.5 68.169.5 0.0964
Table 3 Ophthalmic artery haemodynamics by colour Doppler imaging
Bimatoprost
Bimatoprost+
dorzolamide
Ophthalmic artery
Peak systolic velocity (cm/s)
18:00 39.8613.4 38.2611.2
22:00 38.2611.3 36.269.6
2:00 35.3611.3 36.869.3
4:00 36.6612.0 35.4610.2
6:00 36.5611.5 35.1610.6
p Value 0.5739
End-diastolic velocity (cm/s)
18:00 12.164.5 11.363.7
22:00 11.063.3 11.364.1
2:00 10.164.8 11.064.6
4:00 11.265.5 11.565.4
6:00 11.464.3 10.164.2
p Value 0.1616
Resistance index
18:00 0.69460.063 0.70360.064
22:00 0.70560.065 0.68660.075
2:00 0.71460.077 0.70060.084
4:00 0.70060.072 0.68560.081
6:00 0.68960.060 0.71660.070
p Value 0.0167*
*Statistically signiﬁcant.
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Clinical scienceWhen interpreting IOP ﬁndings some aspects and limitations
of the study design should be considered. In our study, bima-
toprost was administered in the morning instead of the usual
time of administration in the evening. Some studies have
postulated that PGAs and prostamide given in the morning may
provide better IOP control in the night-time hours
10 and both
regimens of dosing of PGAs are equally efﬁcient for mean 24 h
IOP control.
20 However, the evening dosing of PGAs demon-
strates slightly greater daytime efﬁcacy, with lower 24 h IOP
ﬂuctuations.
20 A different dosing regimen of bimatoprost might
therefore result in a different diurnal IOP curve. The above
aspects make the applicability of our study limited until its
results can be veriﬁed and compared with the results of future
studies on an evening dosing schedule of bimatoprost.
Studies examining the effect of latanoprost
11 or bimatoprost
21
on retrobulbar blood ﬂow showed no haemodynamic effect
either for PGAs or for prostamides.
In our study in patients with POAG treated with bimatoprost,
the addition of dorzolamide had a small measurable effect on the
retrobulbar vasculature. Dorzolamide led to a signiﬁcant decrease
of RI in the OA, while the other parameters remained stable.
Some authors found an increase in retrobulbar velocities and
a decrease of the RI after topically applied dorzolamide or
dorzolamide/timolol ﬁxed combination,
22 whereas others
reported lack of any ﬂow changes in the retrobulbar vessels.
23
The OA, unlike the CRA and short posterior ciliary arteries
(SPCAs), is a large calibre vessel, relatively resistant to changes in
IOP.
24 Parallel changes in both the PSVand EDVof the OA have
rarely been observed. In healthy subjects ﬂow velocities were
reduced in response to hypoxia. Hypoxia did not induce PSVand
EDV changes in the OA in patients with glaucoma, possibly
because of pre-existing vasospasm. An increase in EDV and
decrease in RI in the OA were reported in patients with NTG in
response to hypercapnia, which also supports the hypothesis of
pre-existing vasospasm, partially reversed under hypercapnia.
25
Systemic carbonic anhydrase inhibitors did not alter PSV and
EDVof the OA in young healthy volunteers, while their action
in patients with glaucoma has not been studied. The hypothesis
that TCAIs may regulate the vascular spasm of OA in patients
with glaucoma and decrease the ﬂow resistance requires further
investigation. In our study we observed a signiﬁcant decrease of
RI in the OA after adding dorzolamide to bimatoprost. Gallasi
et al
26 reported that an increased RI in the OA was associated
with an approximately sixfold increase of the risk of visual ﬁeld
deterioration, suggesting that RI changes at the level of the OA
may have good prognostic value.
We did not observe any signiﬁcant changes in PSV, EDVor RI
of the CRA. The CRA, as a smaller calibre vessel, is more
sensitive to ﬂuctuations in perfusion pressure, mostly due to
IOP change.
27 Lack of signiﬁcant modiﬁcation of ﬂow velocities
in the CRA may be caused both by no change in IOP (and
perfusion pressure) after adding dorzolamide and by low base-
line IOP. It has been shown by Siesky et al
22 and Harris et al
23
that different baseline IOP levels (19.1 mmHg vs 14.7 mmHg)
and the subsequent different magnitude of IOP reduction (12%
vs 8%) and effects on OPP might contribute to the differences
seen in the retrobulbar vasculature.
Ocular blood ﬂow improvement may be partially caused by
reduction in IOP; clinical studies also speculated on the presence
of another, unknown mechanism, independent of the IOP-
lowering effect. Fuchsjäger-Mayrl et al
28 observed an increase in
blood ﬂow in the temporal neuroretinal rim and cup disc, and
increased fundus pulsation amplitude in eyes treated with
dorzolamide, whereas these changes were not reported in eyes
treated with timolol, although it induced a comparable or even
greater reduction in IOP and a comparable increase in OPP.
Addition of dorzolamide to bimatoprost did not cause any
statistically signiﬁcant differences in the mean SBP, DBP, SOPP,
DOPPand HR, although a tendency towards decreasing mean DBP
and DOPP was observed. In clinical studies dorzolamide appears
rather to have no negative impact on ABP and OPP.
9 22 28 It has
been recently shown by Quaranta et al
29 that timololedorzolamide
ﬁxed combination led to a signiﬁcant reduction in mean 24 h SBP
and DBP, possibly due to the effect of timolol on BP
9; however,
a substantial reduction in IOP counteracted the decrease in DBP
a n dp r o v i d e da ni n c r e a s eo fm e a nD O P P .
Some considerations should be taken into account when
interpreting these ﬁndings. Nine of 25 patients had systemic
hypertension and although the hypertensive treatment was not
changed during the study period, the impact of systemic medi-
cations on BP cannot be excluded. Additionally, nine patients
suffered from systemic hypotension which might contribute to
a relatively low baseline BP. Low baseline BP and the minimal
decrease in BP which was observed between the two phases of
treatment could contribute to a nearly signiﬁcant change in the
mean DBP and DOPP, which would not result in higher ABP.
Finally, daytime and night-time IOP measurements were
performed in the sitting position, which could also add possible
biases to the BP and IOP readings when patients rose from
a supine to a standing position. Taking into account all the
above, our results should be interpreted cautiously and need to
be veriﬁed in further studies.
In summary, in the current study we found that the addition
of dorzolamide hydrochloride 2% to morning-dosed bimatoprost
0.03% had an additive signiﬁcant hypotensive effect on the
night-time IOP curve at 4:00 h but not on the daytime IOP
curve. Dorzolamide added to morning-dosed bimatoprost caused
a lower 24 h IOP ﬂuctuation. Addition of dorzolamide to
bimatoprost resulted in a signiﬁcant decrease in the RI in the
OA. Our results suggest that dorzolamide might improve ocular
Table 4 Central retinal artery haemodynamics by colour Doppler
imaging
Bimatoprost
Bimatoprost+
dorzolamide
Central retinal artery
Peak systolic velocity (cm/s)
18:00 10.062.3 11.062.3
22:00 10.362.8 10.362.2
2:00 9.562.3 9.962.3
4:00 9.462.4 10.062.6
6:00 8.861.9 9.863.0
p Value 0.5423
End-diastolic velocity (cm/second)
18:00 3.461.0 3.661.1
22:00 3.461.1 3.561.2
2:00 3.561.2 3.361.1
4:00 3.261.1 3.261.2
6:00 2.860.9 3.061.4
p Value 0.6246
Resistance index
18:00 0.65560.082 0.67560.066
22:00 0.66760.065 0.67460.078
2:00 0.64060.058 0.66860.079
4:00 0.65460.066 0.68060.074
6:00 0.68060.075 0.68260.081
p Value 0.6375
No change in best corrected visual acuity was found between study visits.
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Clinical scienceblood ﬂow independently of IOP reduction but the mechanism
by which TCAIs inﬂuence the vascular bed remains unknown.
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